MONTREAL, Sept. 06, 2018 (GLOBE NEWSWIRE) — Pediapharm, Inc. (“Pediapharm”) (TSXV: PDP, OTCQX: PDDPF) is pleased to announce that it has entered into definitive agreements to acquire two speciality pharmaceutical companies and also intends to complete a private placement offering for up to CDN$60 million.

Pediapharm logo

PEDIAPHARM is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community.

Medexus logo

MEDEXUS is a Canadian specialty pharmaceutical company focused on the licensing, registration, marketing, sales and distribution of innovative pharmaceutical products in Canada.

Medac Pharm logo

MEDAC PHARMA is a specialty pharmaceutical company focusing on the development and commercialization of treatments for autoimmune diseases and oncology in the United States.


What's New

January 7, 2019
Medexus Files Business Acquisition Report
Read More >

December 17, 2018
Medexus Announces New Chief Executive Officer, Chair of the Board of Directors, Other Organizational Updates and Equity Incentive Grants.
Read More >

December 13, 2018
Pediapharm Announces Name Change, Consolidation and Debenture Repayment.
Read More >


Medexus Pharmaceuticals Inc., D, TSXV